- GBI & PARTNERS
- Vision Medicals takes home RMB 100m in Series A
Vision Medicals takes home RMB 100m in Series A
Guangzhou-based Vision Medicals reportedly raised RMB 100 million (USD 14million) via a Series A financing round, co-led by Volcanics Venture and Cash Capital. The proceeds will be utilized to upgrade pathogenic metagenomics products and rapid gene testing diagnostic products, bolster registration inspections and clinical trials for the firm's first pathogenic metagenomics product and help to co-establish a national medical laboratory network as well as collaborations with Class 3A hospitals in China.
Vision Medicals specializes in gene technology and precision medicine, offering IDseq, a pathogen metagenomics platform, and ID-CRISPR, a pathogen CRISPR-based rapid diagnosis platform. The former enables 24-hour delivery of DNA/RNA dual process testing. In addition, the company has a medical laboratory, research and development center and a Good Manufacturing Practice (GMP)-compliant facility covering a total 3,000 sq.m.